A phase 1/2 study of an adjuvanted varicella-zoster virus subunit candidate vaccine in adult autologous hematopoietic stem-cell transplant recipients.
Stadtmauer EA et al. Blood. 2014 Sep 18. pii: blood-2014-04-573048. [Epub ahead of print].

Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of a Randomized, Placebo-Controlled Phase III Trial.
Schmitt T et al. J Clin Oncol. 2014 Sep 15. pii: JCO.2013.55.0095. [Epub ahead of print].

Bisphosphonates In Multiple Myeloma: A Fractured Consensus.
Kumar S. Leuk Lymphoma. 2014 Sep 16:1-4. [Epub ahead of print].

Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens.
Jung SH et al. Int J Hematol. 2014 Sep 12. [Epub ahead of print].

Prevention of VTE in Cancer Outpatients: guidance from the SSC of the ISTH.
Khorana AA et al. J Thromb Haemost. 2014 Sep 10. doi: 10.1111/jth.12725. [Epub ahead of print].

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M et al. Cochrane Database Syst Rev. 2014 Aug 29;8:CD008500. doi: 10.1002/14651858.CD008500.pub3.

Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network.
Callander N et al. Cancer Chemother Pharmacol. 2014 Aug 29. [Epub ahead of print].